Literature DB >> 15993952

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells.

Anne Wierinckx1, John Brevé, Dominique Mercier, Marianne Schultzberg, Benjamin Drukarch, Anne-Marie Van Dam.   

Abstract

Pro-inflammatory cytokines, e.g. interleukin-1beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFalpha) as well as neurotoxic molecules such as nitric oxide (NO), that are produced and released by activated glial cells, play an important role in inflammation and oxidative stress occurring during Multiple Sclerosis (MS). Reduction of these processes could therefore be of therapeutic interest. Dimethylfumarate (DMF) and sulforaphane (SP) are well known for their detoxicating properties. Furthermore, they have anti-inflammatory effects as shown clinically by the treatment of inflammatory skin diseases. However, their detoxication and anti-inflammatory action on brain-derived cells is unknown. In the present study we have studied, within the same concentration range, the anti-inflammatory and detoxicating effects of DMF and SP on the production and release of mediators of inflammation and detoxication from lipopolysaccharide (LPS) activated primary co-cultures of rat microglial and astroglial cells. DMF and SP attenuated the LPS-induced production and release of TNFalpha, IL-1beta, IL-6 and NO. In addition, DMF and SP increase both mRNA level and activity of NAD(P)H:quinone reductase (NQO-1), a detoxication enzyme, as well as the cellular glutathione content. We conclude that DMF or SP simultaneously can (1) reduce mediators of inflammation and (2) enhance detoxication enzymes in LPS stimulated co-cultures of astroglial and microglial cells. This double-sided effect could potentially be of therapeutic interest.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993952     DOI: 10.1016/j.jneuroim.2005.05.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  41 in total

Review 1.  The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress.

Authors:  Truyen Nguyen; Paul Nioi; Cecil B Pickett
Journal:  J Biol Chem       Date:  2009-01-30       Impact factor: 5.157

Review 2.  Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders.

Authors:  Vittorio Calabrese; Carolin Cornelius; Albena T Dinkova-Kostova; Edward J Calabrese; Mark P Mattson
Journal:  Antioxid Redox Signal       Date:  2010-08-28       Impact factor: 8.401

3.  Dimethyl Fumarate Modulates Oxidative Stress and Inflammation in Organs After Sepsis in Rats.

Authors:  Amanda Della Giustina; Sandra Bonfante; Graciela Freitas Zarbato; Lucinéia Gainski Danielski; Khiany Mathias; Aloir Neri de Oliveira; Leandro Garbossa; Taise Cardoso; Maria Eduarda Fileti; Raquel Jaconi De Carli; Mariana Pereira Goldim; Tatiana Barichello; Fabricia Petronilho
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

4.  Positively Charged Oligo[Poly(Ethylene Glycol) Fumarate] Scaffold Implantation Results in a Permissive Lesion Environment after Spinal Cord Injury in Rat.

Authors:  Jeffrey S Hakim; Melika Esmaeili Rad; Peter J Grahn; Bingkun K Chen; Andrew M Knight; Ann M Schmeichel; Nasro A Isaq; Mahrokh Dadsetan; Michael J Yaszemski; Anthony J Windebank
Journal:  Tissue Eng Part A       Date:  2015-07       Impact factor: 3.845

5.  Emerging oral therapies in multiple sclerosis.

Authors:  Devon Conway; Jeffrey A Cohen
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

6.  Sulforaphane inhibits IL-1β-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of MMPs, COX-2, and PGE2.

Authors:  Yun Jung Choi; Won-Seok Lee; Eun-Gyeong Lee; Myung-Soon Sung; Wan-Hee Yoo
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

Review 7.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

8.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

9.  [Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].

Authors:  M Stangel; D Moharregh-Khiabani; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

Review 10.  Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.

Authors:  Ralf A Linker; Ralf Gold
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.